159 related articles for article (PubMed ID: 38061376)
1. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.
Persaud D; Bryson Y; Nelson BS; Tierney C; Cotton MF; Coletti A; Jao J; Spector SA; Mirochnick M; Capparelli EV; Costello D; Szewczyk J; Nicodimus N; Stranix-Chibanda L; Kekitiinwa AR; Korutaro V; Reding C; Carrington MN; Majji S; Yin DE; Jean-Philippe P; Chadwick EG
Lancet HIV; 2024 Jan; 11(1):e20-e30. PubMed ID: 38061376
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
Ruel TD; Capparelli EV; Tierney C; Nelson BS; Coletti A; Bryson Y; Cotton MF; Spector SA; Mirochnick M; LeBlanc R; Reding C; Zimmer B; Persaud D; Bwakura-Dangarembizi M; Naidoo KL; Hazra R; Jean-Philippe P; Chadwick EG
Lancet HIV; 2021 Mar; 8(3):e149-e157. PubMed ID: 33242457
[TBL] [Abstract][Full Text] [Related]
3. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
4. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
[TBL] [Abstract][Full Text] [Related]
5. Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
Boivin MJ; Maliwichi-Senganimalunje L; Ogwang LW; Kawalazira R; Sikorskii A; Familiar-Lopez I; Kuteesa A; Nyakato M; Mutebe A; Namukooli JL; Mallewa M; Ruiseñor-Escudero H; Aizire J; Taha TE; Fowler MG
Lancet HIV; 2019 Aug; 6(8):e518-e530. PubMed ID: 31122797
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
Lockman S; Hughes M; Sawe F; Zheng Y; McIntyre J; Chipato T; Asmelash A; Rassool M; Kimaiyo S; Shaffer D; Hosseinipour M; Mohapi L; Ssali F; Chibowa M; Amod F; Halvas E; Hogg E; Alston-Smith B; Smith L; Schooley R; Mellors J; Currier J;
PLoS Med; 2012; 9(6):e1001236. PubMed ID: 22719231
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
8. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Nielsen-Saines K; Watts DH; Veloso VG; Bryson YJ; Joao EC; Pilotto JH; Gray G; Theron G; Santos B; Fonseca R; Kreitchmann R; Pinto J; Mussi-Pinhata MM; Ceriotto M; Machado D; Bethel J; Morgado MG; Dickover R; Camarca M; Mirochnick M; Siberry G; Grinsztejn B; Moreira RI; Bastos FI; Xu J; Moye J; Mofenson LM;
N Engl J Med; 2012 Jun; 366(25):2368-79. PubMed ID: 22716975
[TBL] [Abstract][Full Text] [Related]
9. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
Jamieson DJ; Chasela CS; Hudgens MG; King CC; Kourtis AP; Kayira D; Hosseinipour MC; Kamwendo DD; Ellington SR; Wiener JB; Fiscus SA; Tegha G; Mofolo IA; Sichali DS; Adair LS; Knight RJ; Martinson F; Kacheche Z; Soko A; Hoffman I; van der Horst C;
Lancet; 2012 Jun; 379(9835):2449-2458. PubMed ID: 22541418
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD; Acosta EP; Liu JP; Gray KP; George K; Montañez N; Popson S; Buchanan AM; Bartlett M; Dayton D; Anthony P; Brothers C; Vavro C; Singh R; Koech L; Vhembo T; Mmbaga BT; Pinto JA; Dobbels EFM; Archary M; Chokephaibulkit K; Ounchanum P; Deville JG; Hazra R; Townley E; Wiznia A;
Lancet HIV; 2022 May; 9(5):e332-e340. PubMed ID: 35489377
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
Larsen A; Magasana V; Dinh TH; Ngandu N; Lombard C; Cheyip M; Ayalew K; Chirinda W; Kindra G; Jackson D; Goga A
BMC Infect Dis; 2019 Sep; 19(Suppl 1):789. PubMed ID: 31526366
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral interventions for preventing breast milk transmission of HIV.
White AB; Mirjahangir JF; Horvath H; Anglemyer A; Read JS
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD011323. PubMed ID: 25280769
[TBL] [Abstract][Full Text] [Related]
14. Infectious morbidity of breastfed, HIV-exposed uninfected infants under conditions of universal antiretroviral therapy in South Africa: a prospective cohort study.
le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Zerbe A; le Roux DM; Kroon M; Myer L
Lancet Child Adolesc Health; 2020 Mar; 4(3):220-231. PubMed ID: 31932246
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
[TBL] [Abstract][Full Text] [Related]
16. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
17. Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
Aliyu MH; Blevins M; Audet CM; Kalish M; Gebi UI; Onwujekwe O; Lindegren ML; Shepherd BE; Wester CW; Vermund SH
Lancet HIV; 2016 May; 3(5):e202-11. PubMed ID: 27126487
[TBL] [Abstract][Full Text] [Related]
18. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM
BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
Musoke P; Guay LA; Bagenda D; Mirochnick M; Nakabiito C; Fleming T; Elliott T; Horton S; Dransfield K; Pav JW; Murarka A; Allen M; Fowler MG; Mofenson L; Hom D; Mmiro F; Jackson JB
AIDS; 1999 Mar; 13(4):479-86. PubMed ID: 10197376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
